Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Tirzepatide is a GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes mellitus treatment Lightheadedness occurs through reduced fluid intake from gastrointestinal effects, blood pressure lowering from weight loss, or hypoglycaemia when combined with insulin or sulfonylureas Seek immediate medical attention for loss of consciousness, chest pain, severe confusion, or persistent vomiting preventing fluid intake Management includes maintaining adequate hydration (6-8 glasses daily), eating regular small meals, rising gradually from sitting or lying positions, and medication review with your GP Report frequent or concerning lightheadedness to your healthcare team within 24 hours for dose adjustment or investigation of alternative causes Table of Contents Why Mounjaro Can Cause Lightheadedness Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus
The treatment effectively restored antioxidant defenses by increasing GSH and CAT activity while significantly reducing MDA levels
Multiple Endocrine Neoplasia Syndrome Type 2: Contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2
Silverstein and Stephen T
US$ 27.50
US$ 29.24
US$ 24.40
US$ 28.68
US$ 21.58
US$ 27.70
US$ 24.50
